Technical Articles

FGFR4:肝癌靶向治疗为何盯上这条选择性受体
FGFR4: Why Hepatocellular Carcinoma Targeting Focuses on This Selective Receptor
发布时间 2026-09-20
Among the four FGFR family members, FGFR4 alone resides in the liver and binds the KLB co-receptor. From an industry perspective, this article dissects the FGF19 axis, its association with hepatocellular carcinoma and the design logic of selective in
View details
  • Signaling Pathway
  • FGFR4
  • Hepatocellular carcinoma
  • FGF19
  • Selective inhibitor
  • Targeted therapy
  • UA011375
一扇需要两把钥匙的门:FGF19、FGFR4 与 KLB 的开门过程
A Door That Needs Two Keys: How FGF19, FGFR4 and KLB Open the Gate
发布时间 2026-09-20
The FGFR4 door opens only when both keys—FGF19 and KLB—are inserted at the same time. This article walks through the four-step assembly of the FGF19-FGFR4-KLB ternary complex and the full process of signal entry.
View details
  • Signaling Pathway
  • FGFR4
  • FGF19
  • Beta-Klotho
  • KLB
  • Ternary complex
  • Hepatocellular carcinoma
  • UA011375
Total 2
  • 1
Go to